Opioid treatment of experimental pain activates nuclear factor-κB

J Opioid Manag. 2015 Mar-Apr;11(2):115-25. doi: 10.5055/jom.2015.0261.

Abstract

Objective: To determine the independent and combined effects of pain and opioids on the activation of an early marker of inflammation, nuclear factor-κB (NF-κB).

Design: NF-κB activation was compared within-subjects following four randomly ordered experimental sessions of opioid-only (intravenous fentanyl 1 μg/kg), painonly (cold-pressor), opioid + pain, and a resting condition.

Setting: University General Clinical Research Center.

Participants: Twenty-one (11 female) healthy controls.

Interventions: Following exposure to treatment (fentanyl administration and/or cold-pressor pain), blood samples for NF-κB analysis were obtained.

Main outcome measures: Intracellular levels of activated NF-κB, in unstimulated and stimulated peripheral blood mononuclear cells at 15 and 30 minutes.

Results: Neither pain nor opioid administration alone effected NF-κB levels in cell populations; however, the combination of treatments induced significant increases of NF-κB in stimulated peripheral blood mononuclear cell, lymphocytes, and monocytes.

Conclusions: The combination of acute pain with opioids, as occurs in clinical situations, activates a key transcription factor involved in proinflammatory responses.

Publication types

  • Observational Study
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Analgesics, Opioid / therapeutic use*
  • Female
  • Fentanyl / therapeutic use*
  • Follow-Up Studies
  • Healthy Volunteers
  • Humans
  • Injections, Intravenous
  • Male
  • Monocytes / drug effects
  • NF-kappa B / blood*
  • Pain / blood
  • Pain / drug therapy*
  • Signal Transduction / drug effects

Substances

  • Analgesics, Opioid
  • NF-kappa B
  • Fentanyl